Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Esperion Theraptc (ESPR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,496,806
  • Shares Outstanding, K 26,200
  • Annual Sales, $ 0 K
  • Annual Income, $ -74,980 K
  • 36-Month Beta 2.73
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.28

Price Performance

See More
Period Period Low Period High Performance
1-Month
45.09 +28.10%
on 11/15/17
65.20 -11.41%
on 12/01/17
+11.48 (+24.81%)
since 11/14/17
3-Month
42.55 +35.75%
on 10/26/17
65.20 -11.41%
on 12/01/17
+7.09 (+13.99%)
since 09/14/17
52-Week
10.71 +439.31%
on 01/24/17
65.20 -11.41%
on 12/01/17
+45.47 (+369.98%)
since 12/14/16

Most Recent Stories

More News
Esperion Announces the Appointment of Jeffrey Berkowitz to Board of Directors

Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...

ESPR : 57.76 (+1.10%)
Biotech's Flying Under The Radar

Biotech investors spend a ton of time considering what the cure for cancer could be or the next invention that could eliminate a rare disease. It's difficult to keep track of the advancements and developments...

ESPR : 57.76 (+1.10%)
AEZS : 2.22 (-0.89%)
PPCB : 0.1575 (-12.50%)
GERN : 1.97 (-1.99%)
CPRX : 4.10 (-1.20%)
Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...

ESPR : 57.76 (+1.10%)
Esperion to Participate in Fireside Chat at the Jefferies 2017 London Healthcare Conference

Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...

ESPR : 57.76 (+1.10%)
Earnings Review and Free Research Report: Vertex's Revenue Soared 40%; Adjusted EPS Rocketed 212%

Research Desk Line-up: Esperion Therapeutics Post Earnings Coverage

ESPR : 57.76 (+1.10%)
VRTX : 142.53 (-1.57%)
Esperion to Participate in Fireside Chat at the Stifel 2017 Healthcare Conference

Fireside Chat Webcast on Tuesday, November 14, 2017 at 8:45 a.m. Eastern Time

ESPR : 57.76 (+1.10%)
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2017 Financial Results

Esperion Therapeutics, Inc. (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing convenient, complementary, cost-effective, once-daily, oral therapies for the treatment...

ESPR : 57.76 (+1.10%)
Esperion Announces Initiation of Pivotal Phase 3 Study for the Bempedoic Acid / Ezetimibe Combination Pill

- Top-Line Results Expected by the Fourth Quarter of 2018 -

ESPR : 57.76 (+1.10%)
Biotech Stocks on Investors' Radar -- Curis, Egalet, Esperion Therapeutics, and GlycoMimetics

If you want a Stock Review on CRIS, EGLT, ESPR, or GLYC then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. On Wednesday, November 01, 2017, US markets...

ESPR : 57.76 (+1.10%)
CRIS : 0.80 (-3.50%)
EGLT : 1.01 (-0.98%)
GLYC : 16.01 (-2.79%)
Notable Wednesday Option Activity: ESPR, ABMD, THC

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Esperion Therapeutics Inc , where a total volume of 4,114 contracts has been traded...

ESPR : 57.76 (+1.10%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 64% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Average. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Esperion Therapeutics, Inc. is a biopharmaceutical company. It focused on the research, development and commercialization of therapies for low-density lipoprotein cholesterol and other cardiometabolic risk factors. Esperion Therapeutics, Inc. is based in Plymouth, Michigan.

See More

Key Turning Points

2nd Resistance Point 63.29
1st Resistance Point 60.52
Last Price 57.76
1st Support Level 55.85
2nd Support Level 53.95

See More

52-Week High 65.20
Last Price 57.76
Fibonacci 61.8% 44.38
Fibonacci 50% 37.95
Fibonacci 38.2% 31.53
52-Week Low 10.71

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.